Banco Bilbao Vizcaya Argentaria S.A. Sells 3,494 Shares of Humana Inc. $HUM

Key Points

• Banco Bilbao Vizcaya Argentaria S.A. has reduced its stake in Humana Inc. by 42.4%, now holding a total of 4,746 shares worth approximately $1,255,000.
• A number of analysts have adjusted their price targets for Humana, with Bank of America lowering its target from $320.00 to $260.00, while Royal Bank of Canada raised its target from $283.00 to $322.00.
• Humana declared a quarterly dividend of $0.885 per share, representing a dividend yield of 1.2% and an annualized payout of $3.54.

Banco Bilbao Vizcaya Argentaria S.A. lessened its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 42.4% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 4,746 shares of the insurance provider's stock after selling 3,494 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Humana were worth $1,255,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC raised its holdings in Humana by 63.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after buying an additional 46 shares during the last quarter. Riverview Trust Co acquired a new position in Humana during the first quarter worth $34,000. Garde Capital Inc. acquired a new position in Humana during the first quarter worth $36,000. Zions Bancorporation National Association UT acquired a new position in Humana during the first quarter worth $37,000. Finally, Whipplewood Advisors LLC raised its holdings in Humana by 639.1% during the first quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock worth $45,000 after buying an additional 147 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Truist Financial lowered their price objective on shares of Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a report on Wednesday, July 16th. Wall Street Zen lowered shares of Humana from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Barclays set a $275.00 target price on shares of Humana and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Bank of America reduced their target price on shares of Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research note on Tuesday, June 17th. Finally, Morgan Stanley reduced their target price on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a research note on Thursday, July 31st. Seven equities research analysts have rated the stock with a Buy rating and sixteen have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $283.29.

Humana Stock Performance

HUM traded down $1.80 during trading on Thursday, hitting $295.46. 217,851 shares of the company traded hands, compared to its average volume of 1,703,351. The firm has a market cap of $35.54 billion, a P/E ratio of 22.66, a price-to-earnings-growth ratio of 1.76 and a beta of 0.44. The stock's fifty day moving average is $252.05 and its 200 day moving average is $254.08. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. Humana Inc. has a one year low of $206.87 and a one year high of $382.72.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. Humana's quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, equities analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, September 26th. This represents a $3.54 annualized dividend and a yield of 1.2%. Humana's dividend payout ratio is presently 27.17%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.